Although many people still view obesity as the result of a lack of willpower, a growing body of evidence presents this condition as a complex, chronic disease. Losing weight and maintaining weight loss are exceedingly difficult for many overweight and obese individuals. Obesity, a new report from Decision Resources, offers invaluable market intelligence to pharmaceutical companies that are developing drugs to treat this disease.

(Photo: )

Of the therapies in development, the most interesting is Axokine, a drug from Regeneron in Phase III trials. Trial results suggest that Axokine may be the first obesity drug to cause weight loss after people stop taking the drug. We estimate peak-year sales of Axokine in the range of $150-300 million. Some physicians also express interest in the potential use of GlaxoSmithKline's depression and smoking cessation agent, bupropion, for obesity.

The United States will remain the largest and most dynamic market for weight-loss drugs because of the staggering number of obese and overweight individuals and better acceptance of drug treatment for obesity. The majority of weight-loss drug sales will occur in the United States, with the U.S. market representing 74% of sales in 2000, 76% in 2005, and 80% in 2010.

To purchase your copy of Obesity today, or for further information, please contact Tim Daley at 781-296-2636 or email

This study is part of Mosaic, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development. Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

Contact Tim Daley, 781.296.2636 (tel), 781.296.2550 (fax), or

In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or

In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or



AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources

Contact: Tim Daley of Decision Resources, +1-781-296-2636,

Radiolabeled Monoclonal Antibodies Will Fuel Growth in the Non-Hodgkin's Lymphoma Market, According to a Study from Decision Resources

View Now